ARA-290 Peptide and Tissue Protection Based on the available research (8) , the ARA-290 peptide is considered to have potential binding capacity to TPRs, which may assist in maintaining the function of the tissues protecting against harmful inflammation and subsequent cellular and tissue death
In some embodiments, the otic formulation or composition comprises between about 0.01% to about 70% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof
Important Safety Information Do not use AOD-9604 if you: Have a known allergy to growth hormone fragments or any component of the formulation Have been diagnosed with active cancer or have a history of malignancy (use only under medical supervision) Are pregnant or breastfeeding (safety data is lacking) Have severe uncontrolled diabetes or metabolic disorders without medical supervision Common side effects may include: Injection site reactions, mild headaches, temporary fatigue, or slight dizziness during initial use
Mechanistic research has investigated GHK-Cu as a regulator of gene expression in dermal fibroblast research models, with broad effects observed across genes involved in extracellular matrix remodeling, copper homeostasis, antioxidant defense, and tissue signaling (Pickart & Margolina, 2018)
Researchers should follow all storage recommendations provided with the product and avoid excessive heat, moisture, direct sunlight, and environmental contamination
Serious side effects include muscle weakness, extreme thirst, confusion, shortness of breath, headache, exhaustion, reddening of the skin, and a fast or irregular heartbeat
